CytRx’s Executive Vice President and Chief Medical Officer Dr. Daniel Levitt to Present Oncology Grand Rounds at LSU Medical

  CytRx’s Executive Vice President and Chief Medical Officer Dr. Daniel Levitt
  to Present Oncology Grand Rounds at LSU Medical School

Presentation to feature advancements with aldoxorubicin and the broad utility
                    of the novel albumin linker technology

Business Wire

LOS ANGELES -- June 20, 2013

CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development
company specializing in oncology, announced that Executive Vice President and
Chief Medical Officer Daniel Levitt, M.D., Ph.D., will give the Grand Rounds
presentation today to the prestigious Department of Hematology and Oncology at
LSU Medical School in New Orleans. The presentation, “The Diversity of
Albumin-Linked Cancer Drugs,” will focus on advancements in CytRx’s program
with aldoxorubicin, an improved version of the widely used chemotherapeutic
doxorubicin.

Systemically delivered doxorubicin is dose-limited to a level below its
maximum anti-tumor capabilities due to its toxicity, including potential
damage to the heart muscle. Aldoxorubicin combines doxorubicin with a novel
albumin-binding linker platform technology that concentrates doxorubicin at
the site of the tumor, thereby reducing the toxic side effects associated with
systemic delivery. Clinical trials demonstrated that 3.5 to 4 times the
standard dose of native doxorubicin could be safely administered with
aldoxorubicin. CytRx is currently conducting an international Phase 2b
clinical trial with aldoxorubicin as a first-line treatment for soft tissue
sarcomas, and plans to initiate a Phase 3 pivotal trial under a special
protocol assessment (SPA) with aldoxorubicin as a therapy for patients with
soft tissue sarcomas whose tumors have progressed following treatment with
chemotherapy.

CytRx holds the exclusive worldwide rights to aldoxorubicin, as well as option
rights to the linker platform technology.

AboutCytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company
specializing in oncology. The CytRx oncology pipeline is focused on the
clinical development of aldoxorubicin (formerly known as INNO-206), its
improved version of the widely used chemotherapeutic agent doxorubicin. CytRx
is conducting an international Phase 2b clinical trial with aldoxorubicin as a
treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical
trial primarily in the same indication, and has initiated a Phase 1b
pharmacokinetics clinical trial in patients with metastatic solid tumors and a
Phase 1b study of aldoxorubicin in combination with doxorubicin in patients
with advanced solid tumors. The Company is initiating a Phase 3 pivotal trial
under a special protocol assessment (SPA) with aldoxorubicin as a therapy for
patients with soft tissue sarcomas whose tumors have progressed following
treatment with chemotherapy. CytRx is expanding its pipeline of oncology
candidates based on a novel linker platform technology that can be utilized
with multiple chemotherapeutic agents and could allow for greater
concentration of drug at tumor sites. The Company also has rights to two
additional drug candidates, tamibarotene and bafetinib. The Company completed
its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk
B-cell chronic lymphocytic leukemia (B-CLL), and plans to seek a partner for
further development of bafetinib, and is evaluating further development of
tamibarotene. For more information about CytRx Corporation, visit
www.cytrx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of
Section 21E of the Securities Exchange Act of 1934, as amended. Such
statements involve risks and uncertainties that could cause actual events or
results to differ materially from the events or results described in the
forward-looking statements, including risks relating to the outcome, timing
and results of CytRx’s clinical trials, the risk that any future human testing
of aldoxorubicin, the Company’s linker technology and other drug candidates
might not produce results similar to those seen in past human or animal
testing, risks related to CytRx’s ability to manufacture its drug candidates
in a timely fashion, cost-effectively or in commercial quantities in
compliance with stringent regulatory requirements, risks related to CytRx’s
need for additional capital or strategic partnerships to fund its ongoing
working capital needs and development efforts, including the Phase 3 clinical
development of aldoxorubicin, and the risks and uncertainties described in the
most recent annual and quarterly reports filed by CytRx with the Securities
and Exchange Commission and current reports filed since the date of CytRx’s
most recent annual report. All forward-looking statements are based upon
information available to CytRx on the date the statements are first published.
CytRx undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.

Contact:

Investor Relations:
Legend Securities, Inc.
Thomas Wagner
800-385-5790 x152
718-233-2600 x152
twagner@legendsecuritiesinc.com
or
At the Company:
CytRx Corporation
David Haen
Vice President, Business Development
310-826-5648 x304
dhaen@cytrx.com
 
Press spacebar to pause and continue. Press esc to stop.